Trump announces deal to lower prices of some popular weight-loss drugs

President Donald Trump announced a deal on Thursday to lower the prices of some weight-loss drugs, including popular weight loss drugs Zepbound and Wegovy.

The deal is with both Eli Lilly and Novo Nordisk, and is expected to lower the price of obesity drugs to $149 a month in some cases. 

Zepbound and Wegovy will be covered for some patients under Medicare and Medicaid, and will fall from $1,000 and $1,350 per month, respectively, to $350 for others when purchased through the direct-to-consumer government website TrumpRx.

“It’s a triumph for American patients that will save lives and improve the health of millions and millions of Americans,” Trump said.

Eli Lilly said in a statement that it's "in discussions with the administration to further expand patient access, preserve innovation, and promote affordability of our medicines."

Novo Nordisk said it "is engaged in constructive discussions with the Administration regarding the Most Favored Nation executive order. We remain focused on improving patient access and affordability, and we will continue to work to find solutions that help people access the medication they need."